A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- 23 Feb 2018 Planned End Date changed from 1 Nov 2017 to 1 Apr 2018.
- 23 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.